title: [Hormonal treatment of recurrent spontaneous abortions].
abstract: A retrospective study with 79 pregnant women was conducted. All of them were diagnosed as spontaneous abortion. The patients were separated in two group and the women have been treated in two schemes--51%--Utrogestan and 49%--Utrogestan and Profasi. The medication was applied only into the first trimester of the pregnancy. The duration of the therapy was 15.0 +/- 12.34 days. The mean gestational age in this study was 7.6 +/- 3.0 gestational weeks. Women with a first pregnancy and spontaneous abortion were excluded from the study. The number of this hormonal treated pregnancy was 2.84 +/- 1.13. 10.2% of the followed women had 3 and more than 3 miscarriages. The followed group of women was historically and clinically heterogenic. For that reason we think that many other factors could play a role in the optimum outcome of this pregnancy. The criteria for positive result we accepted the vital embryo/fetus on the time of dehospitalization. From these pregnancy only 3 terminated with miscarriage--3.79%. The rest of 96.2% went at home with intact pregnancy. The authors try to find a theoretical support for use of micronized progesterone Utrogestan--there could be some changes in the cellular and humoral immunity at repeated abortions, related to the change of the cytokine production. It could be find an ability to realize a readjustment of the endocrine system of the mother and to control the immune reaction in the fetoplacental unit.
authors.forename: Zh
authors.initials: Zh
authors.lastname: Karag'ozova
authors.forename: T
authors.initials: T
authors.lastname: Chernev
authors.forename: D
authors.initials: D
authors.lastname: Atanasova
authors.forename: E
authors.initials: E
authors.lastname: Pavlova
authors.forename: V
authors.initials: V
authors.lastname: Dimitrova
authors.forename: Iu
authors.initials: Iu
authors.lastname: Khranov
authors.forename: S
authors.initials: S
authors.lastname: Vragaleva
mesh_terms: D000026:Abortion, Habitual / Q000188:drug therapy* / Q000453:epidemiology / Q000276:immunology; D000328:Adult; D000917:Antibody Formation / Q000187:drug effects; D006063:Chorionic Gonadotropin / Q000008:administration & dosage / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D004338:Drug Combinations; D005260:Female; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects; D011247:Pregnancy; D011256:Pregnancy Outcome / Q000453:epidemiology; D011261:Pregnancy Trimester, First; D011374:Progesterone / Q000008:administration & dosage / Q000627:therapeutic use*; D012189:Retrospective Studies
chemical_list: D006063:Chorionic Gonadotropin; D004338:Drug Combinations; C412829:Profasi; D011374:Progesterone